A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination with Nivolumab (BMS-936558) with and without Chemotherapy in Patients with Advanced Pancreatic Cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224088

Enrollment

160

Registered

2018-10-11

Start date

2018-09-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Pancreatic Cancer

Interventions

investigational material(s) Generic name etc : BMS-986227, Nivolumab INN of investigational material : - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investiga

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Must have histological or cytological confirmed diagnosis of locally advanced or metastatic adenocarcinoma of the pancreas, which has progressed on or after one line of chemotherapy ECOG Performance status 0-1 Adequate organ functions Measurable disease

Exclusion criteria

Exclusion criteria: Suspected or known CNS metastasis Participants with active, known, or suspected autoimmune disease Uncontrolled or significant cardiovascular disease Prior exposure to selected immune cell-modulating antibody regimens

Design outcomes

Primary

Measure	Time frame
efficacy Median progression free survival (mPFS)	—

Secondary

Measure	Time frame
safety efficacy Incidence of AE, SAE, death, laboratory abnormalities and AE leading to discontinuation PK parameters Objective response rate (ORR) Median duration of response (MDOR) Overall survival rate (OSR)	—

Countries

Asia except Japan, Japan, North America

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026